Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major. 1976

C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami

2-3-Dihydroxybenzoic acid was evaluated as a potentially useful, orally effective iron-chelating drug by performing iron balance studies in patients with beta-thalassaemia major. The administration of this substance at 25 mg/kg/d to five patients for 8 d caused an average increase in iron excretion of 4.5 mg/d. When the drug was administered at 25 mg/kg q.i.d. to eight patients for 21 d, iron excretion increased to 6.5 mg/d. Chelation was highly specific for iron with changes in magnesium and calcium excretion being insignificant. The drug was well tolerated with side effects limited to gastrointestinal complaints which ameliorated when the drug was taken with food. These studies provide a rationale for further evaluation of 2,3-dihydroxybenzoic acid in patients with iron overload.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D002614 Chelating Agents Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. Chelating Agent,Chelator,Complexons,Metal Antagonists,Chelators,Metal Chelating Agents,Agent, Chelating,Agents, Chelating,Agents, Metal Chelating,Antagonists, Metal,Chelating Agents, Metal
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias

Related Publications

C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
October 2006, British journal of haematology,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
February 1977, Biochemical and biophysical research communications,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
December 2009, Blood reviews,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
October 1967, Biochimica et biophysica acta,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
May 1977, Monatsschrift fur Kinderheilkunde,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
April 2007, Diabetes research and clinical practice,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
May 2022, Vox sanguinis,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
December 2000, The Medical journal of Malaysia,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
January 1976, Birth defects original article series,
C M Peterson, and J H Graziano, and R W Grady, and R L Jones, and H V Vlassara, and V C Canale, and D R Miller, and A Cerami
January 1989, Journal of psychosomatic research,
Copied contents to your clipboard!